Publications by authors named "Ben Shum"
Introduction: Systemic corticosteroids are the mainstay of treatment for immune checkpoint inhibitor induced (CPI) colitis but are associated with complications including life-threatening infection. The topically acting oral corticosteroid beclomethasone dipropionate (BD) is an effective treatment for mild to moderate flares of ulcerative colitis, and has fewer side effects than systemic corticosteroids. We hypothesized that BD would be an effective treatment for CPI-induced colitis.
View Article and Find Full Text PDFArticle Synopsis
- * A high percentage (83%) of patients developed S1-reactive antibodies, but neutralizing antibody levels against virus variants (Alpha, Beta, Delta) were significantly lower, despite stable levels over time.
- * The study indicated that while most patients had detectable SARS-CoV-2-specific T cells and antibody responses, those with blood cancers exhibited weaker immune responses linked to their specific conditions and treatments, yet they still showed some compensatory immune activity.
Patients with cancer are currently prioritized in coronavirus disease 2019 (COVID-19) vaccination programs globally, which includes administration of mRNA vaccines. Cytokine release syndrome (CRS) has not been reported with mRNA vaccines and is an extremely rare immune-related adverse event of immune checkpoint inhibitors. We present a case of CRS that occurred 5 d after vaccination with BTN162b2 (tozinameran)-the Pfizer-BioNTech mRNA COVID-19 vaccine-in a patient with colorectal cancer on long-standing anti-PD-1 monotherapy.
View Article and Find Full Text PDF